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Abstract
Background: Foot infections are a major cause of morbidity in people with diabetes and the most common cause
of diabetes-related hospitalization and lower extremity amputation. Staphylococcus aureus is by far the most frequent
species isolated from these infections. In particular, methicillin-resistant S. aureus (MRSA) has emerged as a major
clinical and epidemiological problem in hospitals. MRSA strains have the ability to be resistant to most β-lactam
antibiotics, but also to a wide range of other antimicrobials, making infections difficult to manage and very costly
to treat. To date, there are two fifth-generation cephalosporins generally efficacious against MRSA, ceftaroline and
ceftobripole, sharing a similar spectrum.
Biofilm formation is one of the most important virulence traits of S. aureus. Biofilm growth plays an important
role during infection by providing defence against several antagonistic mechanisms. In this study, we analysed
the antimicrobial susceptibility patterns of biofilm-producing S. aureus strains isolated from diabetic foot
infections. The antibiotic minimum inhibitory concentration (MIC) was determined for ten antimicrobial
compounds, along with the minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication
concentration (MBEC), followed by PCR identification of genetic determinants of biofilm production and
antimicrobial resistance.
Results: Results demonstrate that very high concentrations of the most used antibiotics in treating diabetic foot
infections (DFI) are required to inhibit S. aureus biofilms in vitro, which may explain why monotherapy with these
agents frequently fails to eradicate biofilm infections. In fact, biofilms were resistant to antibiotics at concentrations
10–1000 times greater than the ones required to kill free-living or planktonic cells. The only antibiotics able to inhibit
biofilm eradication on 50 % of isolates were ceftaroline and gentamicin.
Conclusions: The results suggest that the antibiotic susceptibility patterns cannot be applied to biofilm established
infections. Selection of antimicrobial therapy is a critical step in DFI and should aim at overcoming biofilm disease in
order to optimize the outcomes of this complex pathology.
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Background
Foot infections are a major cause of morbidity in dia-
betes patients and the most common cause of diabetes-
related hospitalization and lower limb amputation [1].
The physiopathology of diabetic foot infections (DFI) is
complex, but its severity and prevalence are a conse-
quence of host-related disorders and pathogens-factors,
as virulence and antibiotic resistance traits [1]. DFI are
mostly polymicrobial and Staphylococcus aureus is by far
the more frequent species involved, either alone or as a
component of mixed infections [2, 3].
S. aureus is an important nosocomial pathogen that
can cause several infections such as: bacteraemia, osteo-
myelitis, skin infections, pneumonia, meningitis and
endocarditis. In particular, MRSA has emerged as a
major clinical and epidemiological problem in hospitals
since the 1980s [4]. MRSA strains have the ability to re-
sist to all β-lactam antibiotics and also to a wide range
of other antimicrobials, making MRSA infections costly
and difficult to manage [5]. Ceftaroline and ceftobiprole
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are, to date, the only anti-MRSA cephalosporins that in-
hibit PBP2a (penicillin binding protein 2a) at therapeut-
ically concentrations. Ceftobiprole, already evaluated in
clinical trials, access the active site of PBP2a by its R2
group, whereas ceftaroline causes an allosteric change in
PBP2a [6]. Ceftaroline is FDA approved for treatment of
skin and skin structure infections, including those
caused by MRSA [6].
Several structural and secreted virulence factors play a
role in S. aureus infections, which are multifactorial and
depend on bacterial adherence and biofilm formation. In
the beginning of an infection, S. aureus produces numer-
ous surface proteins, called “microbial surface components
recognizing adhesive matrix molecules” (MSCRAMM)
that mediate adherence to host tissues. Once S. aureus ad-
heres to host tissues, it can form biofilms, which enable its
persistence by allowing bacteria to evade host defences,
impeding access to certain types of immune cells, such as
macrophages, which display incomplete penetration
into the biofilm matrix and “frustrated phagocytosis”
[7]. Additionally, biofilm cells display increased toler-
ance to antibiotics [8].
In contrast to heritable antibiotic resistance mecha-
nisms, biofilm-associated tolerance is a transient state in
which normally susceptible bacteria display an altered
physiology that decreases sensitivity. When these cells dis-
perse and re-enter in a planktonic state, they present their
normal susceptibility profile [9]. Bacteria embedded within
a biofilm are difficult to eradicate due to a wide variation
of nutrient gradients that slow or arrest bacterial growth,
protein synthesis, and other physiologic activities; bacteria
sequestered in biofilms are less susceptible to antibiotics
by virtue of their reduced growth rates [10]. Other factors
that contribute to biofilm-mediated antimicrobial resist-
ance include inefficient diffusion or sequestering of the
agent within biofilm matrix, the presence of “persister”
cells and other unknown phenotypic differences [10].
Various genes have been implicated in the onset and
maintenance of biofilms by staphylococci. Among these,
the most extensively studied are icaA and icaD (intercellu-
lar adhesion A and B), products of a gene locus composed
by the genes icaR (intercellular adhesion regulator) and
ica A, B, C, and D (intercellular adhesion ABCD), respon-
sible for the synthesis of polysaccharide intercellular
adhesin (PIA), which contains N-acetylglucosamine, a
major component of the exopolysaccharide matrix that
surrounds bacterial cells in the biofilm [11]. Also, the
products of pls (plasmin sensitive) which encodes a sur-
face protein, and atl (autolysin) which encodes an autoly-
sin, have been implicated in the formation and structuring
of biofilms. The atl is the most predominant peptidogly-
can hydrolase in staphylococci, and was also identified as
an adhesin involved in primary attachment of cells to
polystyrene surfaces [12]. The pls is a homologue of the
serine-aspartate repeat (Sdr) surface protein family, of
which ClfA (clumping factor A) is the best-characterized
member, that reduces adhesion to host proteins and cellu-
lar invasiveness [13].
In this study, a collection of S. aureus strains isolated
from DFI was characterized in terms of their planktonic
and biofilm susceptibility patterns, and presence of biofilm
and antibiotic resistance genes. The antibiotic minimum in-
hibitory concentration (MIC) was determined, along with
the minimum biofilm inhibitory concentration (MBIC) and
minimum biofilm eradication concentration (MBEC),
followed by PCR identification of genetic determinants of
biofilm production and antimicrobial resistance.
Methods
Strains
A total of 53 staphylococci clinical isolates from diabetic
foot ulcers (DFU), obtained from 49 samples, were col-
lected in a previous epidemiological survey, as described
by Mendes et al. in 2012 [2]. From this collection,
twenty-three (n = 23) representative biofilm-producing S.
aureus isolates were selected, based on Pulse Field Gel
Electrophoresis (PFGE) and Multilocus Sequence Type
(MLST) analysis, previously performed by our research
team [14]. A reference strain, S. aureus ATCC 29213, a
known biofilm producer, was also included in this study.
Antimicrobial agents
The antibiotics cefoxitin (FOX), ciprofloxacin (CIP),
clindamycin (CLI), doxycycline (DOX), erythromycin
(ERY), gentamicin (GEN), linezolid (LZD), meropenem
(MEM) and vancomycin (VAN) were obtained from
Sigma-Aldrich (Portugal). AstraZeneca (Portugal) gener-
ously provided ceftaroline (CPT). All antibiotics were
prepared according to CLSI guidelines [15].
Minimum inhibitory concentrations
MIC were determined for all antibiotics to all strains; e-
test was performed according to the manufacturer’s rec-
ommendations (Biomérieux). Test performance was
monitored using the reference strain S. aureus ATCC
29213.
Biofilm susceptibility tests
A modified version of the Calgary Biofilm Pin Lid Device
(CBPD) [16] was used to determine the antimicrobial
susceptibility of bacteria embedded in a 24-h biofilm, in
order to determine the MBIC and MBEC [16, 17].
Briefly, a starting inoculum of 5×105 CFU/mL in Mueller
Hinton Broth (MHB, Liofilchem Italy) was distributed in
96-well flat-bottom microtiter plates (Nunc, Roskilde,
Denmark), covered with a 96-peg lid (Imuno TSP; Nunc,
Roskilde, Denmark) and statically incubated for 24-h at
35 °C, to allow biofilm formation on the pegs [18, 19].
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The peg lid was then rinsed three times in 1X sterile
PBS to remove planktonic bacteria, placed on a new
plate filled with 200 μL of fresh broth containing serial
dilutions of antibiotics, from 1024 μg/ml to 0.5 μg/ml,
and incubated for 24-h at 37 °C [17–20]. After incuba-
tion, the peg lid was removed and the MBIC value was
recorded and defined as the last well in which there was
no visible growth after incubation [17, 21]. Next, to de-
termine the MBEC value, the peg lid was rinsed three
times in 1X sterile PBS, placed in a new plate filled with
200 μL of fresh MHB and sonicated at 45–60 Hz during
10 min [17, 22], in order to disperse the bacteria from
the peg surface. After sonication, the peg lid was dis-
carded and the plate was covered with a normal lid and
incubated for 24-h at 37 °C. After incubation, the quan-
tification of biofilm formation was conducted according
with a previously described colorimetric microtiter plate,
using Alamar Blue [23]. Briefly, 5 μl of resazurin (Ala-
mar Blue, AB, ThermoScientific, Spain) was added to the
wells and the plates were incubated for one hour at 37 °
C. After incubation, absorbance (A) values at 570 nm
and 600 nm were recorded in a microplate reader (BMG
LABTECH GmbH, Germany). Controls included media
plus Alamar Blue (control one) and bacterial cells plus
media plus AB without antibiotic (control two). The
MBEC was defined as the lowest drug concentration
resulting in ≤1/2 the absorbance value when compared
to control two. Assays were performed at least twice and
the average absorbance values used to determine the
MBEC values.
PCR screening of biofilm associated and antibiotic
resistance genes
All strains were investigated to detect the presence of
genes associated with biofilm formation, namely: icaA,
icaD, atl and pls. Genes associated with antibiotic resist-
ance were also screened, namely: blaZ (penicillin resist-
ance); mecA and mecC (oxacillin resistance); tetK, tetL,
tetM and tetO (tetracycline resistance); msrA, ermA,
ermB and ermC (erythromycin resistance); aac(6′)-
aph(2″) (gentamicin resistance) and norA (ciprofloxacin
resistance).
Detection of mecA gene and its homologous mecC were
performed by multiplex PCR [24]. Oligonucleotide primer
sequences are described in Table 1. All amplification reac-
tions were prepared with a mixture containing: 12.5 μl of
Supreme NZYTaq 2x Green Master Mix (NZYTech,
Portugal), 1 μl of each primer (forward and reverse)
(STABVIDA Lda, Portugal) and 5.5 μl of sterile water
(water for molecular biology, NZYTech, Portugal). To this
mixture, 1 μl of the previous extracted DNA was added,
resulting in a total reaction volume of 25 μl. PCR amplifica-
tion was performed in a thermal cycler (MyCycler Thermal
Cycler, Bio-Rad, Portugal) using conditions described in the
references reported in Table 1. Positive controls for the
tested genes were gently provided by: Dr. Mark
Holmes (University of Cambridge, England), Dr. Penadés
(Cardenal Herrera University, Valencia, Spain) and Dr. Bir-
git Strommenger (Robert Koch Institute, Berlin, Germany).
Results
Minimum inhibitory concentrations
All isolates were considered susceptible to vancomycin,
linezolid and doxycycline, with MIC values ≤1 μg/ml,
≤4 μg/ml and ≤0.5 μg/ml respectively. Ceftaroline MIC
Table 1 PCR target genes and primers used in this work
Gene Primer Reference
Sequence (5′→3′)
icaA TCTCTTGCAGGAGCAATCAA Arciola et al. (2001) [46]
AGGCACTAACATCCAGCA
icaD ATGGTCAAGCCCAGACAGAG Arciola et al. (2001) [46]
CGTGTTTTCAACATTTAATGCAA
atl CTTCAGCACAACCAAGATC Petrelli et al. (2008) [4]
GGTTACCGACTGCACCGTCAC
pls GTAATACAACAGGAGCAGATGG Petrelli et al. (2008) [4]
GTAGCTTTCCATGTTTTTCCTG
blaZ ACTTCAACACCTGCTGCTTTC Martineau et al. (2000) [38]
TGACCACTTTTATCAGCAACC
mecA TCCAGATTACAACTTCACCAGG Stegger et al. (2012) [24]
CCACTTCATATCTTGTAACG
mecC GAAAAAAAGGCTTAGAACGCCTC Stegger et al. (2012) [24]
GAAGATCTTTTCCGTTTTCAGC
tetK TCGATAGGAACAGCAGTA Ng et al. (2001) [47]
CAGCAGATCCTACTCCTT
tetL TCGTTAGCGTGCTGTCATTC Ng et al. (2001) [47]
GTATCCCACCAATGTAGCCG
tetM GTGGACAAAGGTACAACGAG Ng et al. (2001) [47]
CGGTAAAGTTCGTCACACAC
tetO AACTTAGGCATTCTGGCTCAC Ng et al. (2001) [47]
TCCCACTGTTCCATATCGTCA
msrA TCCAATCATTGCACAAAATC Martineau et al. (2000) [38]
AATTCCCTCTATTTGGTGGT
ermA TATCTTATCGTTGAGAAGGGATT Martineau et al. (2000) [38]
CTACACTTGGCTTAGGATGAAA
ermB CTATCTGATTGTTGAAGAAGGATT Martineau et al. (2000) [38]
GTTTACTCTTGGTTTAGGATGAAA
ermC CTTGTTGATCACGATAATTTCC Martineau et al. (2000) [38]
ATCTTTTAGCAAACCCGTATTC
aac(6′)–aph(2″) TTGGGAAGATGAAGTTTTTAGA Martineau et al. (2000) [38]
CCTTTACTCCAATAATTTGGCT
norA TTCACCAAGCCATCAAAAAG Pourmand et al. (2014) [48]
CTTGCCTTTCTCCAGCAATA
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values were ≤0.5 μg/ml and only two isolates presented
MIC ≥4 μg/ml (ceftaroline-resistant). All isolates, except
for one, originated MIC values for clindamycin of ≤0.5
μg/ml. Gentamicin MIC values were ≤1 μg/ml, except
for three resistant isolates. About 57 % of isolates were
considered susceptible to ciprofloxacin with MIC ≤2 μg/
ml, and 65 % were erythromycin susceptible with
MIC ≤0.5 μg/ml. Eight isolates (35 %) were cefoxitin-
resistant, with MIC values ≥8 μg/ml (Tables 2 and 3).
Biofilm susceptibility tests
MBIC and MBEC concentration values are summarized
in Table 2. For MRSA isolates, cefoxitin MBIC concen-
trations ranged from two to five dilutions higher than
MIC values, reaching values of 256 to 1024 μg/ml, while
MBEC values were even higher (from 2 to ≥1024 μg/ml).
Instead, for methicillin-susceptible S. aureus (MSSA)
isolates MBIC and MBEC values for cefoxitin were the
same as MIC values, with the exception of four isolates,
for which MBIC and MBEC values were two times
higher when compared to MIC. In 65 % of the isolates
(n = 15), MBIC and MBEC values for linezolid were the
same, and one thousand times higher when compared
with MIC values (Fig. 1).
Other antibiotics originated different results. All MBIC
and MBEC values were much higher than the respective
MIC values, and MBEC values were at least twice higher
than the MBIC ones. Ceftaroline MBIC values were four
to sixteen times higher than MIC values, ranging from
0.5 to 8 μg/ml, except for one MRSA isolate that
reached 1024 μg/ml; and the MBEC concentrations
reached 1024 μg/ml, including four of the eight MRSA
isolates. Regarding ciprofloxacin, MBIC values achieved
an average of eight times higher compared with MIC,
ranging from 0.5 to 512 μg/ml, except one isolate that
reached 1024 μg/ml; for all isolates, except for two,
MBEC values increased from 256 to 512 μg/ml. Similar
results were obtained for clindamycin, but the gap be-
tween the MIC and MBIC values was higher, with MIC
of 0.03 to MBIC of 0.5–128 μg/ml, except for one isolate
that reached a MBIC value of 1024 μg/ml. MBIC values
for doxycycline were even higher, as half of the isolates
reached a MBIC concentration of 0.5 to 2 μg/ml, three
hundreds to one thousand times higher than MIC. The
other half showed MBIC values of 32 to 512 μg/ml, one
thousand times higher than the respective MIC. Doxy-
cycline MBEC values ranged from 64 to 128 μg/ml
(Fig. 1).
The biofilm inhibition concentrations for erythro-
mycin increased about four times in comparison with
the values for MIC, from 0.12 - >256 μg/ml to 0.5 -
>256 μg/ml. For MRSA, MIC and MBIC values were the
same and equal to >256 μg/ml. These isolates reached
MBEC concentrations of 64 - >1024 μg/ml, representing
an increase of five hundred to one thousand times com-
pared with MIC and MBIC values (except for the resist-
ant isolates). In the case of gentamicin, it was observed
an increase from MIC to MBIC of two to five hundred
times higher, reaching values of 0.5 - >128 μg/ml (except
for one MRSA isolate, that showed MBIC value of
1024 μg/ml); MBEC reached 256 μg/ml (including six of
the eight MRSA isolates). Meropenem and vancomycin
produced the major increase regarding MBEC values,
being one thousand times higher than the value of MIC,
and five hundred times higher than the MBIC values
(0.5 to >1024 μg/ml and 8 to >1024 μg/ml for merope-
nem and vancomycin, respectively). The MBIC values
ranged from 0.5 to 32 μg/ml for meropenem and from 1
to 16 μg/ml for vancomycin, except for one isolate that
reached 1024 μg/ml (Fig. 1).
PCR screening of biofilm associated and antibiotic resistance
genes
All isolates were positive for the biofilm associated genes
icaA, icaD and atl, and negative for pls. Eight isolates
(35 %) were MRSA harbouring the mecA gene and were
resistant to cefoxitin. None of the isolates presented the
mecC gene. Three isolates presented the blaZ gene, one
of which was MRSA and resistant to six of the antibi-
otics tested (Table 3).
Regarding the tet genes, none of the isolates were posi-
tive for tetL and tetO, one MRSA isolate was positive for
tetM (and also blaZ positive), and tetK was found in
three MSSA isolates. With the exception for two isolates,
the erythromycin-resistant isolates were positive for erm
genes, namely six for ermA (five MRSA and one MSSA)
and three for ermC (two MRSA and one MSSA); con-
trariwise, none of these isolates was positive for ermB
and msrA genes. The aac(6′)-aph(2″) gene was found in
three isolates, one MRSA and two MSSA. Nineteen
Table 2 In vitro MIC, MBIC and MBEC values for the antibiotics tested against S. aureus DFU isolates (*CLSI range susceptibility)
Antimicrobial agents
FOX CPT CIP CLI DOX ERY GEN LZD MEM VAN
MIC range 1.5–256 0.064–38 0.06- >32 0.015–0.06 0.064–0.125 0.12- >256 0.06–64 1–2 0.015–16 0.25–1
MBIC range 2–256 0.5–8 0.5–512 0.5–128 0.5–512 0.5- >256 0.5- >128 1- >1024 0.5–32 1–16
MBEC range 2–1024 0.5–1024 256–512 64- >1024 64–128 64- >1024 1- >256 4- >1024 0.5- >1024 8- >1024
FOX, cefoxitin (≤4 μg/ml*); CPT, ceftaroline (≤0.5 μg/ml *); CIP, ciprofloxacin (≤4 μg/ml *); CLI, clindamycin (≤0.25 μg/ml*); DOX, doxycycline (≤4 μg/ml*); ERY,
erythromycin (≤8 μg/ml*); GEN, gentamicin (≤4 μg/ml*); LZD, linezolid (≤4 μg/ml*); MEM, meropenem (≤4 μg/ml*); VAN, vancomycin (≤2 μg/ml*)
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isolates (82 %) presented the norA gene, six of which
were MRSA and thirteen were MSSA (Table 3).
Discussion
The diversity of bacterial populations in chronic wounds,
such as diabetic foot ulcers, and the biofilm mode of
growth of the infecting organisms, may be important con-
tributors to the chronicity of wounds [25]. As expected, all
isolates carried the genes icaA, icaD and atl, due to their
virulence profile and ability to form biofilm. None of the
isolates were positive for pls gene, and this may suggest
the adhesion and cellular invasiveness properties of the
studied isolates, considering that the MRSA surface pro-
tein pls reduces these virulence features [13, 26].
Biofilm formation, as widely described in literature, rep-
resents a big obstacle for the clinical efficacy of antibiotics,
and the results of antimicrobial susceptibility testing can-
not be directly applied to bacterial biofilm infections, due
to higher probability of failure [27]. Biofilm can resist even
to antibiotic concentrations 10–10.000 times higher than
the ones needed to kill planktonic cells [10]. In this study,
antibiotic concentrations required to inhibit or eradicate
biofilm were much higher than the respective MIC values
and should not be clinically applied. Furthermore, MBEC
values were often several times higher than MBIC values.
Although all MRSA isolates should be considered as
resistant to β-lactams in vivo [15], almost all isolates
were susceptible to meropenem. MBIC values for this
antibiotic were thirty to one thousand times higher than
MIC, being still in the range of susceptibility, however
meropenem was unable to eradicate biofilm. The results
suggested that cefoxitin is able to inhibit and eradicate S.
aureus biofilms formed by MSSA isolates.
PCR amplification of mecA is considered the “gold
standard” technique for detection of methicillin resist-
ance among S. aureus [28]. However, the discovery of a
Table 3 Antibiotic resistance phenotypes and genotypes of S. aureus DFU isolates
Isolate Resistance
Phenotype Gene
FOX CIP CPT CLI DOX ERY GEN LZD MEM VAN blaZ mecA mecC ermA ermB ermC msrA norA tetK tetL tetM tetO aac(6′)-aph(2″)
I01 R R S S S S S S I S - + - + - - - + - - - - +
I02 S R R S S S S S S S - - - - - - - + - - - - -
I03 S S S S S S S S S S - - - - - - - + - - - - -
I04 S S S S S S S S S S - - - - - + - + - - - - -
I05 S S S S S S S S S S - - - - - - - + - - - - -
I06 R R S S S R S S S S - + - + - - - + - - - - -
I07 R R S R S R R S R S + + - - - - - + - - + - -
I08 R R R S S R S S I S - + - - - + - - - - - - -
I09 R R S S S R S S R S - + - - - + - - - - - - -
I10 S R S S S R S S R S - - - + - - - + - - - - -
I11 S S S S S S S S S S - - - - - - - + - - - - -
I12 S S S S S S S S S S + - - - - - - + - - - - -
I13 S I S S S S R S S S - - - - - - - + + - - - +
I14 S S S S S S R S S S + - - - - - - + + - - - +
I15 R R S S S R S S S S - + - + - - - + - - - - -
I16 S S S S S S S S S S - - - - - - - - + - - - -
I17 R R S S S R S S S S - + - + - - - + - - - - -
I18 R R S S S R S S S S - + - + - - - + - - - - -
I19 S S S S S S S S S S - - - - - - - - - - - - -
I20 S S S S S S S S S S - - - - - - - + - - - - -
I21 S S S S S S S S S S - - - - - - - + - - - - -
I22 S S S S S S S S S S - - - - - - - + - - - - -
I23 S S S S S S S S S S - - - - - - - + - - - - -
R, resistant; S, susceptible; I, intermediate; +, positive in specific PCR; −, negative in specific PCR. FOX, cefoxitin; CIP, ciprofloxacin; CPT, ceftaroline; DOX,
doxycycline; ERY, erythromycin; GEN, gentamicin; LZD, linezolid; MEM, meropenem; VAN, vancomycin. blaZ, penicillin resistance; mecA and mecC, oxacillin
resistance; ermA, ermB, ermC and msrA, erythromycin resistance; norA, ciprofloxacin resistance; tetK, tetL, tetM and tetO, tetracycline resistance; aac(6′)-aph(2)”,
gentamicin resistance
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new mecA homologous gene, mecC, determined the
need to establish new detection protocols [24], although
normally the screening of the homologous gene is only
performed in oxacillin-resistant mecA negative isolates
[29]. In this study, a multiplex assay was applied for the
screening of mecA and mecC in all isolates, being pos-
sible to detect the mecA gene in 35 % of the S. aureus
DFU isolates (n = 8). By the contrary, mecC was not de-
tected in any isolates, which is not surprising because
MRSA isolates harbouring mecC are currently rare, and
have only been reported in 13 European countries to
date, not including Portugal [30]. The presence of mecA
positive strains among the study isolates can be associ-
ated with the increasing prevalence of antibiotic-resist-
ant bacteria in DFU isolates, particularly MRSA, as
described by Bowling et al. [31]. Also, Djahmi et al.
suggested that MRSA prevalence may be related with
the increase of antimicrobial treatment required, consider-
ing the high frequency of recurrent ulcers [32]. Nowadays,
penicillin resistance is present in about 90 % of human S.
aureus isolates. Two mechanisms are involved: the pro-
duction of β-lactamases encoded by the blaZ gene and an
altered penicillin-binding protein, PBP2a, encoded by
mecA [33, 34]. In our study, only three isolates were posi-
tive for blaZ. This may be due to the primers used, be-
cause multiple polymorphisms within the blaZ gene have
already been identified and the results can vary when dif-
ferent regions of the gene are targeted [34], or may also be
due to the fact that the isolates express penicillin resist-
ance encoded by mecA.
Antibiotic susceptibility tests showed that gentamicin
and ceftaroline were the most potent agents against S.
aureus biofilms, reaching clinical concentrations that
can be applied to inhibit and eradicate biofilms. This
was observed even for the MRSA isolates, since ceftaro-
line and gentamicin were effective in inhibiting biofilm
production by seven of the eight MRSA isolates, while
ceftaroline was effective in eradicating biofilm produc-
tion by half of the MRSA isolates and gentamicin was ef-
fective in eradicating biofilm production by two isolates
MRSA isolates. Today ceftaroline represents a good al-
ternative to treat infections by S. aureus with reduced
susceptibility to current agents, as recent studies have
proven its efficacy against biofilm, applied alone or in
combination [35, 36].
In 1999, Ceri et al. [16] already described the efficacy
of gentamicin against S. aureus biofilms, as well as other
studies that followed [20, 37]. The aac(6′)-aph(2'') is the
gene coding for the most frequently encountered amino-
glycoside modifying enzyme (AME) in Gram-positive
bacteria, which inactivates a broad range of clinically
useful aminoglycosides, especially gentamicin and tobra-
mycin; this enzyme is bifunctional because it catalyses
both acetyltransferase and phosphotransferase reactions
[38]. The aac(6′)-aph(2'') gene was found in three iso-
lates, one MRSA and two MSSA, with no discrepant
Fig. 1 Minimum inhibitory concentration (MIC), minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration
(MBEC) of S. aureus DFU isolates as determined by a modified version of the Calgary Biofilm Pin Lid Device. FOX, cefoxitin; CIP, ciprofloxacin; CPT,
ceftaroline; DOX, doxycycline; ERY, erythromycin; GEN, gentamicin; LZD, linezolid; MEM, meropenem; VAN, vancomycin
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results with the resistance phenotypes obtained by e-
test. These findings are in agreement with other studies,
which reported that all aminoglycoside-resistant strains
carried the aac(6′)-aph(2'') gene [38].
Linezolid lacked activity against staphylococci biofilms
because it didn’t inhibit or eradicate biofilms, as already
reported in other studies [18, 20, 39]. Clindamycin,
doxycycline and vancomycin were effective against
planktonic cultures and inhibited biofilm produced by
most isolates; however, these antibiotics showed no
ability to eradicate biofilms. This may suggest that these
agents, although effective against bacteria in suspen-
sions, may not be the most suitable antibiotics for treat-
ing biofilm related infections. Previous studies have
shown that these antibiotics lack activity against
staphylococci grown in biofilms [17–19, 39, 40].
Although isolates presented a high rate of resistance to
ciprofloxacin and erythromycin, their MBIC concentra-
tions were about eight times higher than MIC values but
were still clinically adequate. They were not able to
eradicate biofilm, as previously described for ciprofloxa-
cin in other studies [16, 18]. Several genes are implicated
in erythromycin resistance, especially in staphylococci
and streptococci. The gene ermA is located on the trans-
poson Tn554 and has a single specific site for insertion
into S. aureus chromosome; the ermB gene is located on
the transposon Tn551 of a penicillinase plasmid; the
ermC gene is generally located on small plasmids and is
responsible for constitutive or inducible resistance to
erythromycin [38]. Staphylococcal strains resistant to
macrolides and type-B streptogramins also frequently
harbor msrA, which encodes an ATP-dependent efflux
pump [38]. In this study, ermA was found in five resist-
ant and one sensible erythromycin staphylococci. Re-
garding ermC, this gene was less frequently found than
ermA, namely in two resistant and one sensible erythro-
mycin staphylococci. These results are according to pre-
vious reports, in which ermA was the most prevalent
erm-gene followed by ermC [38, 41, 42]. The discrepance
between the erythromycin susceptible isolates and their
erm positivity was already described [38]. Numerous
factors could explain the sensitive phenotype in these
strains, including regulation of erm genes and absence
of host factors associated with the expression of
erythromycin resistance. These factors can also ex-
plain the cefoxitin-susceptible S. aureus isolates carry-
ing the mecA gene.
The increasing prevalence of MRSA has led to a new
interest in the usage of macrolide-lincosamide-
streptogramin B (MLSB) antibiotics to treat S. aureus
infections, with clindamycin being the preferred agent
due to its excellent pharmacokinetics. However, this in-
creased application promoted a raise in resistance to
MLSB antibiotics. Clindamycin resistance is commonly
caused by a one target site modification mediated by
erm genes, difficult to detect in vitro, as they appear
erythromycin resistant and clindamycin sensitive [43].
Tetracycline resistance determinants are widespread
among bacterial species, consisting in active efflux
pumps that result from acquisition of plasmid-located
genes, tetK and tetL, and in ribosomal protection medi-
ated by transposon or chromosomal located genes tetM
or tetO [30, 42]. MRSA isolates typically show tetM or
tetKM genotype; tetK is the most frequent genotype
found in S. aureus, followed by tetM [39, 43, 44]. The
same was observed in this study, in which three MSSA
isolates were tetK positive and one MRSA was tetM
positive; tetL and tetO were not found. Tet-positive iso-
lates were sensible to doxycycline. In tetK positive iso-
lates, this gene confers high resistance to tetracycline,
oxytatracycline, chlortetracycline but low resistance to
monocycline, 6-demethyl-6-deoxytetracycline and doxy-
cycline [44]. Surprisingly, the only tetM positive isolate
was doxycycline sensible. Since this gene is believed to
confer resistance to all drugs of tetracycline group [45],
it may be suggested that prevalence of resistance to
tetracyclines in S. aureus is underestimated or, as dem-
onstrated by Trzcinski et al. [45], recognition of tetracyc-
line resistance in S. aureus strains often depends on the
different interpretation guidelines used.
In recent years, an increase in fluoroquinolone resist-
ance in S. aureus, including MIC strains, has been
spreading worldwide. Resistance mechanisms to these
antibiotics involve mutations within the gyrA and gyrB
genes, which encode for subunits of DNA gyrase, an
established target of fluoroquinolones; analogous muta-
tions in grlA and grlB, which encode for subunits of
DNA topoisomerase IV; and the increased expression of
the norA gene, which encodes for a drug efflux protein,
norA, and mutations in the norA coding region [45, 46].
NorA is a membrane protein which actively transports
norfloxacin and other hydrophilic fluoroquinolones out
of the bacterial cell, thus effectively decreasing the intra-
cellular concentration of the drugs [45]. Nineteen iso-
lates were positive for norA gene but eleven of them
were susceptible to ciprofloxacin.
From a clinical perspective, the discrepancy between
genotype and phenotypic resistance expression suggest
that a susceptible strain harbouring, but not expressing,
an antibiotic resistance gene should be regarded as poten-
tially resistant to that antibiotic. Overall, we did not detect
a significant presence of antibiotic resistance genes, com-
pared to the great biofilm resistance of the isolates, even
when using high antimicrobial concentrations.
Conclusions
To our knowledge, this is the first study on antibiotic
susceptibility tests targeting biofilm-producing S. aureus
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isolates from diabetic foot infections. It was found that
only very high concentrations of the most used antibi-
otics in DFU were capable to inhibit S. aureus biofilms
in vitro, which may explain why monotherapeutics fre-
quently fail to eradicate biofilm infections. Biofilms were
resistant to antibiotics concentrations 10 to 1000 times
higher than the concentrations needed to kill free-living or
planktonic cells. This high level of resistance in biofilms
makes chronic infections, like DFI, extremely difficult to
eradicate using conventional antimicrobial therapy.
MIC values were not always predictive of the MBIC
and MBEC values. Only gentamicin and ceftaroline
proved to be effective in eradicating biofilms, formed by
half of isolates at clinical drug concentrations, while the
other tested drugs were only able to inhibit adherent
cells. In particular, ceftaroline showed a very good po-
tential for inhibiting and eradicating biofilms produced
by MRSA isolates. It is clear that antibiotic susceptibility
values for planktonic populations are not necessarily ap-
plicable to effective treatment of infections by the same
organism, once a biofilm has been established. These dif-
ferences may be an important factor in the selection
of antimicrobial therapy for most of DFI, to whom S.
aureus is the main virulent organism involved, rendering
important the investigation of antibiotic susceptibility of
biofilm infections.
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